This Week In Medicine
Welcome to This Week in Medicine - Your Filtered Medical Journal SummaryLooking to stay up-to-date with the latest medical research but short on time? This Week in Medicine has you covered!Our AI generated podcast provides you with a convenient, on-the-go solution to keep you informed about the most significant developments in the medicine field. We understand that your time is valuable, so we've done the hard work for you.Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers. With This Week i...
NEJM November 12 2026 Prevention of Venous Thromboembolism after Total Hip or Knee Replacement
A recent clinical trial investigated the prevention of blood clotsfollowing elective hip or knee replacement surgeries by comparing three different medications: aspirin, warfarin, and rivaroxaban. Over a thirty-day treatment period, nearly eighteen thousand patients were randomly assigned to one of these three drug regimens, with outcomes monitored for half a year. Researchers assessed both effectiveness, measured by mortality rates and symptomatic blood clots, and safety, which tracked incidents like bleeding or cardiac events. Ultimately, the trial concluded that aspirin failed to meet the noninferiority threshold compared to the two anticoagulants regarding effectiveness. Conversely, warfarin and rivaroxaban did not achieve noninferi...
NEJM November 12 2026 Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
A recent multicenter clinical trial investigated whether taking aspirin alone is as effective as starting with rivaroxaban before transitioning to aspirin for preventing dangerous blood clots following hip and knee replacement surgeries. Researchers randomly assigned over five thousand patients to receive either the single-drug aspirin regimen or the combined rivaroxaban-then-aspirin treatment for several days post-surgery. The primary measurements tracked the development of symptomatic venous thromboembolism alongside any potential bleeding complications over a ninety-day monitoring period. Ultimately, the data demonstrated that the aspirin-only approach successfully achieved noninferiority regarding clot prevention compared to the combined medication strategy. Furthermore, both treatment groups experienced sim...
NEJM November 5, 2026 Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis
Recent clinical research evaluated the effectiveness of plozasiran, an innovative RNA-based therapy, in treating individuals diagnosed with severe hypertriglyceridemia. Across two closely monitored trials involving 757 participants, patients received either the targeted medication or a placebo to measure changes in fasting lipid levels over a one-year period. The findings revealed that administration of the drug resulted in dramatic triglyceride reductions compared to the control group. Furthermore, patients treated with plozasiran experienced a substantially lower incidence of acute pancreatitiswithout an increase in overall adverse events. Ultimately, the investigation demonstrates that this therapeutic approach effectively manages dangerous lipid elevations and significantly mitigates pancreati...
NEJM November 5, 2026 Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain
A recent clinical trial investigated whether performing computed tomographic (CT) coronary angiography could lower the long-term risk of heart-related complications in emergency department patients whose heart attacks were initially excluded. Researchers across the United Kingdom monitored over 3,100 intermediate-risk participants who were randomly split to receive either specialized CT imaging or traditional medical management. Over a median tracking period of three years, the incidence of fatal cardiac events and subsequent heart attacks was evaluated. Ultimately, the findings demonstrated no significant difference in primary cardiovascular outcomes between the two approaches. Consequently, routine CT scanning did not prove superior to standard care in preven...
NEJM November 5 , 20026 Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
A recent clinical trial investigated the effectiveness of retatrutide, an innovative triple-hormone receptor agonist, for managing obesity in adults. Over an eighty-week period, participants received weekly injections of the medication or a placebo to measure changes in body weight, knee osteoarthritis pain, and obstructive sleep apnea severity. The findings revealed that individuals treated with the drug experienced substantial weight loss compared to the placebo group. Furthermore, patients taking the medication showed notable improvements in joint discomfort and respiratory disturbances during sleep, with gastrointestinal issues noted as the most frequent side effects. Ultimately, the research concluded that this therapeutic compound offers promin...
JAMA October 2026 Risk-Based vs Annual Breast Cancer Screening The WISDOM Randomized Clinical Trial
A large-scale clinical trial involving more than 28,000 women was conducted to evaluate whether risk-based breast cancer screening serves as a viable substitute for traditional annual mammography. By utilizing genetic testing, polygenic risk scores, and clinical models, participants in the experimental group were assigned customized screening schedules tailored to their specific vulnerability levels. The findings demonstrated that this personalized approach successfully safely stratified participants without increasing the detection of advanced-stage tumors, though it paradoxically failed to lower overall biopsy rates despite requiring fewer mammograms. Ultimately, the research highlights that while tailored screening optimizes resource allocation and matches clinical intensity to individua...
JAMA October 2026 Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer The HORIZON-Breast06 Randomized Clinical Trial
The HORIZON-Breast06 clinical trial investigated the effectiveness of trastuzumab rezetecan compared to standard chemotherapy for individuals suffering from ERBB2-low advanced breast cancer. Conducted across numerous medical centers in China, the multi-center study randomly divided 551 eligible participants into two distinct treatment groups. The primary focus of the research was to measure progression-free survival rates among both chemotherapy-naive patients and the broader participant pool. Findings revealed that the novel drug substantially extended progression-free survival compared to traditional chemotherapy options, showing consistent advantages across various patient subgroups. Ultimately, the therapy established its potential as a promising alternative treatment, despite noting a higher fre...
NEJM Oct 22 2026 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis
A recent international clinical trial investigated whether shortening antibiotic regimens for left-sided infective endocarditis is safe and effective once patients achieve clinical stability. Researchers compared a response-tailored strategy—which stopped antibiotics earlier—against the standard six-week duration across more than 500 participants. The findings revealed that the tailored approachsuccessfully increased the number of days patients spent free of medication without increasing major safety risks like mortality or surgery. However, this shorter treatment method carried a trade-off, resulting in a statistically higher rate of infection relapse compared to the conventional timeline. Ultimately, the study demonstrates that while individualized antibiotic duration offers greater freedom...
NEJM Oct 22 2026 Ianalumab for the Treatment of Patients with Sjögren’s Disease
Two clinical studies, NEPTUNUS-1 and NEPTUNUS-2, evaluated the effectiveness of the antibody ianalumab as a potential medical intervention for Sjögren's disease, a complicated autoimmune condition lacking specialized treatments. Researchers divided hundreds of participants into groups to compare monthly or quarterly subcutaneous injections of the medication against a placebo over the course of a year. The primary objective measured changes in disease activity scores at week 48 using standardized rheumatology indexes. Findings revealed that monthly dosesachieved a statistically significant reduction in disease severity compared to inactive treatments, despite showing no meaningful differences in specific secondary symptom evaluations. Although participants receiving the drug exp...
NEJM Oct 22 2026 Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
A recent clinical trial investigated whether the medication milvexian could safely lower the chances of secondary heart attacks and strokes in individuals recovering from acute coronary syndrome. Researchers administered either milvexian or a placebo alongside standard antiplatelet treatments to over fourteen thousand participants in this global study. Ultimately, the investigation was halted early because an interim review determined the drug failed to show any benefit in preventing major cardiovascular events. Furthermore, the data revealed no significant difference in severe bleeding rates between the group receiving milvexian and those given the placebo. Scientists ultimately concluded that adding milvexian to conventional therapy does not...
JAMA October 2026 Out-of-Pocket Costs for Chronic Illness Management in High-Deductible Health Plans
A recent retrospective study examined out-of-pocket expenses for working-age adults managing common chronic conditions like diabetes and hypertension. Researchers analyzed national commercial insurance claims from 2022 to 2023 to compare financial burdens between high-deductible health plans and traditional coverage. The findings revealed that patients enrolled in high-deductible policiesfaced annual costs that were roughly 1.6 to 2.4 times greater when seeking standard, evidence-based treatments. Despite this proportional increase, the actual monetary difference remained relatively modest, ranging between roughly $64 and $86 per year. Ultimately, this research offers valuable insight into the financial challenges chronically ill patients navigate depending on their specific insurance structure.
JAMA October 2026 Patient Navigation Plus mHealth Incentives for Linkage to OUD Care for Adults Who Also Use Methamphetamines A Pilot Randomized Clinical Trial
This clinical trial investigated a mobile health strategy combined with patient navigation to improve outpatient care for hospitalized adults struggling with both opioid use disorder and methamphetamine use. Researchers randomly assigned participants to receive either standard treatment or an intervention featuring financial rewards for medication adherence and dedicated support during the first month following discharge. The study successfully met its enrollment goals and demonstrated high patient satisfaction, proving that the program was both practical and well-received. Although participants in the experimental group showed slightly higher rates of connecting with outpatient care after thirty days compared to the control group, the difference w...
JAMA October 2026 Digital and Coaching Interventions for Uptake of Cancer Genetic Testing The MiGHT Randomized Clinical Trial
The Michigan Genetic Hereditary Testing trial explored how to increase low completion rates for hereditary cancer genetic testing. Researchers evaluated nearly eight hundred adult participants who qualified for genetic evaluation across three different groups. Individuals were randomly assigned to receive either telephone-based health coaching, a self-directed digital tool, or standard care. The findings demonstrated that the digital intervention significantly improved early testing rates at six months, whereas health coaching effectively increased testing uptake over a twelve-month period. Ultimately, these alternative strategies successfully boosted testing uptake compared to standard care, highlighting the value of motivational messaging and digital delivery models in clinical c
JAMA Cardiology October 2026 Global, Regional, and National Burden of Heart Failure, 1990-2023 A Systematic Analysis for the Global Burden of Disease Study 2023
A recent cross-sectional analysis utilizing Global Burden of Disease methodologies evaluates the worldwide impact and underlying causes of heart failure across 204 countries and territories from 1990 to 2023. By synthesizing extensive data, the research revealed an estimated 56.0 million cases globally in 2023, with prevalence rates consistently rising alongside advancing age. The study highlights that specific causes vary dramatically depending on geographic region and age group, noting issues like ischemic and hypertensive heart disease in older populations alongside congenital, rheumatic, and alcohol-related conditions in younger cohorts. Because heart failure represents a growing global health challenge, targeting modifiable risk factors such as high blood pressure...
JAMA Cardiology October 2026 Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease
recent systematic review and meta-analysis investigated how aggressively reducing blood pressure impacts heart health and renal function in adults. By examining twenty-seven randomized trials encompassing nearly ninety thousand participants, researchers compared intensive and standard blood pressure management strategies. The findings revealed that aggressive blood pressure reduction significantly lowers cardiovascular event risks by fifteen percent for every ten-millimeter decrease in systolic pressure, regardless of whether a patient has underlying kidney disease. Although this aggressive approach raised the likelihood of moderate, sustained declines in estimated glomerular filtration rates, it did not increase the actual incidence of kidney failure. Because baseline heart disease r...
JAMA October 2026 Development and Validation of an Adult Medical Urgency Score for US Donor Heart Allocation
A recent observational study utilized registry data from adult heart transplant candidates to create and validate the US Candidate Risk Score (US-CRS) as a replacement for the current six-status allocation framework. This new quantitative model relies on specific laboratory values and mechanical support devices to more accurately assess a patient's risk of mortality while waiting for an organ. By incorporating physiological interactions rather than relying solely on therapy types, the proposed system successfully mitigates vulnerabilities to manipulationpresent in the older method. Consequently, simulations demonstrate that implementing the US-CRS framework better prioritizes genuinely ill candidateswho face the highest risk of dying be...
JAMA October 2026 Advance Care Planning for Black and White Older Adults With Serious Illness The EQUAL ACP Randomized Trial
The EQUAL ACP randomized trial investigated whether facilitated advance care planning outperforms self-guided methods for seriously ill older adults. Researchers evaluated completion rates over one year among nearly eight hundred Black and White participants aged sixty-five and older across multiple Southern clinics. Overall results indicated no statistically significant difference in completion between the two strategies when analyzed strictly within individual racial groups. However, pooled data analysis revealed a significant interaction between race and intervention, suggesting that the facilitated method held greater effectiveness for Black participants compared to White participants. Ultimately, the study highlights that while racial background influenced intervention response, ne...
JAMA October 2026 Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease The NOPARK Randomized Clinical Trial
A recent phase 3 clinical trial investigated whether the supplement nicotinamide riboside could slow the progression of early-stage Parkinson disease. Researchers across eleven centers in Norway administered either the substance or a placebo to 393 participants over a 52-week period. To measure disease severity, the study tracked changes using standard movement and non-motor symptom scales. Ultimately, the findings revealed that patients taking the supplement experienced worse clinical outcomes compared to those receiving the inactive treatment. Consequently, experts concluded that this compound is ineffective as a therapeutic intervention for the condition.
NEJM 10 8 2026 Vasopressors or Fluids in Early Septic Shock
Vasopressors or Fluids in Early Septic Shock
NEJM 10 8 2026 Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
NEJM 10 8 2026 Tricuspid-Valve Intervention in Heart Failure
Researchers conducted a clinical trial to determine whether transcatheter tricuspid-valve repair could improve health outcomes for older adults suffering from severe tricuspid regurgitation and heart failure risks. Participants were randomly divided to receive either the combined procedure with medical treatment or standard medication alone. At the one-year mark, the evaluation showed significantly better results for the valve-repair cohort regarding overall mortality, cardiac hospitalizations, and enhanced life quality. Furthermore, tracking the patients over a three-year period revealed that those who underwent the intervention experienced a dramatically lower rate of death and readmissioncompared to the control group. Ultimately, the findings demonstrate that ad...
NEJM 10 1 2026 Giredestrant plus Everolimus in Advanced Breast Cancer
Giredestrant plus Everolimus in Advanced Breast Cancer
NEJM 10 1 2026 Obexelimab for the Treatment of IgG4-Related Disease
A recent phase 3 clinical trial investigated obexelimab, a novel monoclonal antibody that suppresses B-cell function without destroying the cells, as a potential therapy for IgG4-related disease. Standard treatments typically rely on glucocorticoids, which often cause significant toxicity and frequently lead to relapses once stopped. To test the medication, 194 patients were randomly assigned to receive either weekly subcutaneous injections of obexelimab or a placebo while systematically tapering off steroids. The findings demonstrated that obexelimabsubstantially reduced the likelihood of disease flare-ups, prolonged the duration of remission, and lowered the overall requirement for rescue steroid medications compared to the placebo group. Ultima...
NEJM 10 1 2026 Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
JAMA 9 2026Intrauterine Mepivacaine Instillation vs Placebo for Pain During IUD Placement A Randomized Clinical Trial
This clinical study investigates whether applying a local anesthetic directly into the uterus can alleviate the discomfort typically associated with IUD insertion for women who have never given birth. By comparing the effects of mepivacaine against a saltwater placebo, researchers discovered that the medication significantly lowered pain scores and improved the overall tolerability of the procedure. These findings are vital because reducing physical distress can enhance patient autonomy and encourage more individuals to choose highly effective contraceptive methods. Ultimately, the trial demonstrates that a simple intrauterine instillation serves as an effective tool for improving the medical experience and satisfaction of patient
JAMA 9 2026 Medicare Advantage Enrollment and Access to Kidney Transplant After the 21st Century Cures Act
This retrospective study evaluates whether the expansion of Medicare Advantage eligibility for patients with end-stage kidney disease has impacted their ability to receive life-saving treatments. By comparing data from 2021 through 2023, researchers discovered that those enrolled in private Medicare Advantage plans faced significantly lower rates of kidney transplantation and new wait-listing compared to those in traditional Medicare. These disparities were most pronounced among younger beneficiaries, suggesting that private plan structures may inadvertently create barriers to high-value surgical care. Ultimately, the text serves as a call for increased policy oversight to ensure that the growing number of patients in these managed care pl...
JAMA 9 2026 Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion The ATTENTION LATE Randomized Clinical Trial
This clinical study investigated whether administering the clot-busting drug tenecteplase prior to a surgical thrombectomy would benefit patients experiencing a severe stroke in the back of the brain. Researchers focused specifically on individuals who arrived at the hospital in a late time window, between 4.5 and 24 hours after their symptoms began. The trial discovered that adding the medication did not lead to higher rates of functional independence or better recovery compared to performing the surgery alone. Ultimately, the results suggest that for this specific type of stroke and timeframe, the supplemental drug treatment offers no additional clinical advantage in patient outcomes...
NEJM 9 17 2026 Trial of a Maternal Diet Rich in Eggs and Peanuts to Reduce Infant Allergy
This clinical study investigated whether a mother’s diet during pregnancy and breastfeeding could influence the development of food sensitivities in children with a high genetic risk for allergies. Researchers compared a group of women who consumed large quantities of eggs and peanuts to a control group following a standard diet to see if early allergen exposure via the womb or breast milk offered protection. Despite the intensive dietary intervention, the results showed no significant reduction in allergy ratesamong infants by one year of age. Ultimately, the trial concludes that maternal consumption of common allergens does not appear to be an eff...
NEJM 9 17 2026 Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock
This clinical study investigated whether administering sodium bicarbonate could improve outcomes for intensive care patients suffering from metabolic acidosis and circulatory shock. Researchers conducted a randomized trial to determine if correcting blood acidity would reduce major adverse kidney events or lower the risk of death for those already requiring blood pressure support. The results demonstrated that there was no significant clinical benefit to using this treatment compared to a placebo, as rates of organ failure and mortality remained largely unchanged between the two groups. Ultimately, the text concludes that this common intervention does not effectively prevent renal dysfunction or improve...
NEJM 9 17 2026 Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal
This study investigates whether extending the time between follow-up screenings for patients who have had high-risk polyps removed compromises their long-term health. By comparing a five-year surveillance interval against the standard three-year recommendation, researchers sought to determine if less frequent monitoring is just as effective at preventing the development of colorectal cancer. The interim findings reveal that waiting longer for a follow-up did not lead to a higher rate of disease, establishing that the five-year gap is statistically noninferior to more frequent testing. Ultimately, these results suggest that for certain patients, extending the duration between colonoscopies is a safe and via...
JAMA 9 2026 Low-Voltage Ablation in Persistent Atrial Fibrillation The IDEAL-AF Randomized Clinical Trial
This study investigated a more comprehensive surgical strategy for treating persistent atrial fibrillation, a heart rhythm disorder that often resists standard medical interventions. While the traditional approach focuses solely on isolating the pulmonary veins, researchers tested whether targeting specific scarred areas, known as low-voltage zones, would lead to better patient outcomes. The results revealed that patients who received this individualized ablation experienced significantly higher rates of arrhythmia-free survival and a better overall quality of life compared to those receiving the standard treatment. Ultimately, the trial demonstrates that mapping and neutralizing these damaged electrical regions provides a superior clinical benefit without i...
JAMA 9 2026 Adoption of Adjunctive Azithromycin for Unscheduled Cesarean Delivery and Postpartum Infections
This research study examines how clinical practices evolved following a 2016 discovery that adding the antibiotic azithromycin to standard care significantly lowers the risk of postpartum infections for those undergoing unplanned cesarean sections. By analyzing over a decade of health data, the authors found a substantial increase in the administration of this medication during surgical births in the years following the trial's publication. This shift in medical protocol successfully correlated with a meaningful decline in infection rates among new parents, proving that the medical community effectively translated scientific evidence into improved patient outcomes. Ultimately, the text serves as a testament to how ev...
NEJM 9 10 2026 Complete Revascularization Guided by Functional Coronary Angiography in STEMI
This study explores how doctors can best provide complete revascularization for heart attack patients who have blockages in multiple arteries. By comparing two different diagnostic approaches, the researchers discovered that using functional coronary angiography—which assesses the actual physiological impact of a blockage—significantly outperforms traditional visual inspection. Patients whose treatment was guided by this physiology-based strategyexperienced a notably lower risk of major complications, such as death or subsequent heart attacks, compared to those evaluated through standard angiography. Ultimately, the trial demonstrates that targeting lesions based on their functional significance leads to safer and more effective outcomes for high-risk cardiac pat...
NEJM 9 10 2026 Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
This clinical study evaluates the effectiveness of obinutuzumab, a targeted antibody therapy, compared to the traditional drug tacrolimus for treating a specific kidney disorder called primary membranous nephropathy. By tracking patients over two years, researchers discovered that those receiving obinutuzumab were significantly more likely to achieve complete remission, meaning their protein levels normalized while their kidney function remained stable. While both treatments carried similar risks for serious adverse events and infections, the antibody therapy demonstrated a clear clinical superiority in long-term disease resolution. Ultimately, the text highlights a major shift in potential treatment strategies, suggesting that this newer intravenous medicatio...
NEJM 9 10 2026 Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
This study investigates a breakthrough gene-editing treatment known as exa-cel, which modifies a patient’s own blood-building cells to stimulate the production of fetal hemoglobin. By targeting children as young as five who suffer from sickle cell disease or transfusion-dependent β-thalassemia, researchers aimed to eliminate the most debilitating symptoms of these genetic disorders. The clinical results were remarkable, as every evaluable participant achieved complete freedom from blood transfusions or painful vascular blockages for over a year. Despite these clinical triumphs, the process remains intensive, as patients experienced significant side effectsprimarily linked to the aggressive preparatory chemotherapy required before the modified...
Circulation 8 2026 Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease
This research study investigates whether bempedoic acid can effectively protect patients with peripheral artery disease (PAD) from severe leg-related complications. By analyzing data from a large clinical trial of individuals who could not tolerate statins, researchers discovered that this medication significantly decreased the risk of both initial and repeat limb events, such as emergency surgeries or severe blockages. The findings emphasize that managing cholesterol is vital for preventing major adverse cardiovascular events, offering a powerful alternative treatment for those at high risk of disability or limb loss. Ultimately, the study highlights bempedoic acid as a critical tool in reducing the ove...
Circulation 8 2026 Semaglutide and the Inflammatory Pathways to Cardiovascular Health
This study explores how the medication semaglutide reduces the risk of major heart-related events by targeting chronic inflammation in patients with cardiovascular disease. Researchers tracked a specific protein marker, hsCRP, and discovered that lowering this indicator significantly improved patient survival regardless of initial weight or cholesterol levels. Crucially, the drug’s ability to dampen the inflammatory responsehappened rapidly and functioned independently of weight loss, suggesting the treatment protects the heart through multiple biological pathways. Ultimately, the findings highlight that semaglutide’s success in preventing strokes and heart attacks is driven largely by its potent anti-inflammatory effects.
JAMA August 2026 Methadone vs Buprenorphine-Naloxone in Opioid Overdose Survivors
This study evaluates whether methadone or buprenorphine-naloxone is more effective at preventing mortality among high-risk individuals who have recently survived an opioid overdose. By tracking thousands of patients in Ontario over a several-year period, researchers discovered that those who began a methadone regimen experienced a lower risk of death within the first year compared to those prescribed the alternative. A key factor in this outcome appeared to be treatment retention, as patients stayed on methadone for a longer duration than those on buprenorphine-naloxone. However, the data also suggests that the protective benefits of both drugs are similar while actively taking...
JAMA August 2026 Arginine Therapy for Sickle Cell Disease Acute Pain Episodes
This clinical trial investigated whether administering intravenous arginine could effectively alleviate the intense pain crises commonly experienced by young patients with sickle cell disease. Although previous smaller studies suggested that this amino acid might reduce hospital stays and the need for heavy narcotics, this rigorous phase 3 study was halted early for futility after finding no significant benefits. The researchers discovered that arginine was no more effective than a placebo in shortening the time to crisis resolution or decreasing total opioid consumption. Ultimately, the study concludes that despite the biological link between arginine deficiency and pain, this specific therapy does not off...
JAMA August 2026 Predictive Utility of Coronary Artery Calcium Score Added to the PREVENT Atherosclerotic Cardiovascular Disease Equations
This study examines whether measuring coronary artery calcium (CAC)—a marker of plaque buildup—improves the accuracy of a new medical tool called the PREVENT equations for predicting heart disease risk. Researchers analyzed data from over 6,000 adults to see if adding these heart scans to standard risk assessments helped doctors better categorize patients' 10-year chances of suffering a cardiovascular event. While the results showed only a modest improvementin overall predictive power, the data specifically justifies the selective use of CAC scoring for patients who fall into "borderline" or "intermediate" risk groups. Ultimately, the findings suggest that while the scans aren't nec...